A Phase I, Open Label, Dose Ascending Study of BCX1777 (Oral) in Patients With Recurrent or Refractory T/NK-Cell Malignancies.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Forodesine (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Mundipharma International
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2013 Planned number of patients changed from 10 to 24 as reported by ClinicalTrials.gov.
- 15 Jan 2013 Planned End Date changed from 1 Aug 2010 to 1 Dec 2016 as reported by ClinicalTrials.gov.